Literature DB >> 34272627

Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery.

Mojin Wang1, Shubang Cheng2, Lili Zhu1, Tao Xu1, Jinglin Zhang1, Yujie Zhang1, Jie Ping3, Rui Wang4.   

Abstract

BACKGROUND AND AIM: The selection criteria and long-term outcomes of endoscopic therapy (ET) for gastric neuroendocrine tumors (G-NETs) remain controversial.
METHODS: Using Surveillance, Epidemiology, and End Results (SEER) Program database, we assessed the prevalence of metastasis of early G-NETs and long-term outcomes of ET in G-NET patients with good/moderate differentiation and no muscularis propria (MP) involvement.
RESULTS: A total of 2207 patients with stage T1 and T2 G-NETs were included. The depth of invasion into MP [odds ratio (OR) 4.581, 95% confidence interval (CI) 2.571-8.162; P < 0.001] and size of > 20 mm (OR 5.656, 95% CI 2.002-15.975; P = 0.001) were significantly associated with metastasis. The 5-year overall survival (OS) and cancer-specific survival (CSS) of the ET group were similar to the surgery group (91.11% vs. 91.09%, P = 0.750; 99.26% vs. 99.01%, P = 0.173). In the multivariable Cox proportional hazards regression models adjusting for age, gender, race, year of diagnosis, SEER region, depth of tumor invasion, site of cancer, tumor size, and chemotherapy, procedures employed (ET or surgery) had no significant impact on the OS [hazard ratio (HR) 1.189; 95%CI 0.721-1.961; P = 0.498] and CSS (HR 0.684; 95% CI 0.021-22.727; P = 0.832).
CONCLUSIONS: The long-term outcome of survival did not appear to differ between ET and surgery in G-NETs with good/moderate differentiation, ≤ 20 mm size, and no MP involvement.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Endoscopic therapy; Neuroendocrine tumors; Retrospective study; SEER program; Stomach; Surgery

Mesh:

Year:  2021        PMID: 34272627     DOI: 10.1007/s10620-021-07143-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  5 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Risk factors of lymph node metastasis in patients with gastric neuroendocrine tumor with normal serum gastrin level.

Authors:  Ji Hoon Jung; Kee Don Choi; Young Wha Koh; Young Soo Park; Hwoon-Yong Jung; Gin Hyug Lee; Ho June Song; Do Hoon Kim; Kwi-Sook Choi; Jeong Hoon Lee; Ji Yong Ahn; Mi-Young Kim; Suh Eun Bae; Jin-Ho Kim
Journal:  Hepatogastroenterology       Date:  2015 Jan-Feb

3.  [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].

Authors:  Xinli Ma; Wenyi Zhao; Chun Zhuang; Xiaosong Wang; Lin Tu; Ming Wang; Yongwei Sun; Hui Cao
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2017-09-25

4.  Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection.

Authors:  Yuichi Sato; Manabu Takeuchi; Satoru Hashimoto; Ken-ichi Mizuno; Masaaki Kobayashi; Mitsuya Iwafuchi; Rintaro Narisawa; Yutaka Aoyagi
Journal:  Hepatogastroenterology       Date:  2013-09

5.  The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection.

Authors:  Hyung Hun Kim; Gwang Ha Kim; Ji Hyun Kim; Myung-Gyu Choi; Geun Am Song; Sung Eun Kim
Journal:  Gastroenterol Res Pract       Date:  2014-02-17       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.